Lv5
1150 积分 2024-04-25 加入
Reduced IL-2 Intensity Is Associated with Improved Outcomes in Tumor-Infiltrating Lymphocyte Therapy: A Meta-Analysis
5天前
已关闭
Autocrine p40 enhances the efficacy of CLDN18.2 CAR-T cells in gastrointestinal cancer
1个月前
已完结
S1454 Long-Term Efficacy and Safety of Intravenous (IV) Tulisokibart in Patients With Ulcerative Colitis (UC): Results From the Open-Label Extension (OLE) Period of the Phase 2 ARTEMIS-UC Study
1个月前
已关闭
S1877 Duvakitug, an Anti-TL1a mAb, Demonstrates Efficacy and Favorable Safety as an Induction Treatment in Adults With Moderately to Severely Active Ulcerative Colitis: Results From the RELIEVE UCCD Phase 2b Basket Trial
1个月前
已关闭
Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study
2个月前
已完结
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
2个月前
已完结
Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis
2个月前
已完结
Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
4个月前
已完结
Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial
4个月前
已完结
The efficacy and safety of fexuprazan in treating erosive esophagitis: a phase III, randomized, double‐blind, multicenter study
4个月前
已完结
皖公网安备34019202002308
